Geoffrey Beran Rose Sells 6,947 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) insider Geoffrey Beran Rose sold 6,947 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total value of $21,744.11. Following the completion of the transaction, the insider now owns 386,331 shares in the company, valued at $1,209,216.03. The trade was a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Pulmonx Trading Up 6.7%

Shares of NASDAQ:LUNG traded up $0.20 during midday trading on Friday, hitting $3.17. The company had a trading volume of 1,036,300 shares, compared to its average volume of 316,044. Pulmonx Co. has a 12 month low of $2.83 and a 12 month high of $9.37. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market cap of $127.62 million, a price-to-earnings ratio of -2.20 and a beta of 0.52. The firm has a fifty day simple moving average of $4.27 and a 200 day simple moving average of $5.95.

Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.01. The business had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, analysts predict that Pulmonx Co. will post -1.55 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Jefferies Financial Group assumed coverage on Pulmonx in a research report on Monday, March 10th. They issued a "buy" rating on the stock. Piper Sandler restated an "overweight" rating and issued a $9.00 price target (down from $10.00) on shares of Pulmonx in a research report on Thursday, May 1st. Morgan Stanley started coverage on Pulmonx in a research report on Monday, March 10th. They issued an "equal weight" rating on the stock. D. Boral Capital restated a "buy" rating and issued a $17.00 price target on shares of Pulmonx in a research report on Thursday, May 1st. Finally, Citigroup reduced their price target on Pulmonx from $6.50 to $4.15 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Pulmonx presently has an average rating of "Moderate Buy" and an average target price of $11.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in Pulmonx during the fourth quarter worth about $43,000. ProShare Advisors LLC bought a new position in Pulmonx during the fourth quarter worth about $72,000. Stifel Financial Corp bought a new stake in shares of Pulmonx during the fourth quarter worth $81,000. Vontobel Holding Ltd. bought a new stake in shares of Pulmonx during the first quarter worth $82,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Pulmonx by 27.0% in the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock valued at $106,000 after purchasing an additional 3,310 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.